The Passing Of Larry Edelson

Editor Note from Dudley Pierce Baker http://CommonStockWarrants.com Today we learned of the passing of Larry Edelson at the young age of 61. While I never met Larry, he was a colleague of ours in the business and was an incredible talent of great knowledge. I was a subscriber of Larry’s and always looked forward to seeing his next comments on the big picture in the world’s markets and so much more. I am also particularly proud to say that Larry was a subscriber to my services for many years. Our sympathies and respect go out to Larry’s family, Martin Weiss and the entire Weiss Research organization. A life cut short and which we will greatly miss. Larry Edelson, a great man and dear friend of many years, has just passed away. All of us, including his wonderful family, my wife and I, plus his many devoted colleagues at Weiss Research, are in shock and in mourning. One day he appeared well and upbeat. One week later, he was gone. Larry himself, however, seems to have prepared, well in advance, for this last phase in his life cycle much as he prepared for the next phase of the historical cycles he watched so avidly. His last letter to you is below. Once you’ve read it, please stand by. In about 15 minutes, I will follow up with another email to you with more details about our plans. — Martin Last Letter From Larry Edelson to His Loyal Subscribers Dear Dudley, Larry … Continue reading

American Manganese TSXV:AMY – WHERE WILL ALL THE ELECTRIC CARS GO WHEN THEY END THEIR SERVICE LIFE?

  March 2, 2017 Editors Note from Dudley Pierce Baker American Manganese is interesting company which we own and should be of interest to investors. http://JuniorMiningNews.com       WHERE WILL ALL THE ELECTRIC CARS GO WHEN THEY END THEIR SERVICE LIFE? “… Of all the hurdles that electric cars have had to overcome, one of the most annoying, and persistent, has been what to do with the batteries when the vehicles reach the end of their service life. he shell of an electric vehicle (EV) is much the same as that of any gas-powered automobile: a mix of metal, plastics and some fabric. Comprehensive recycling programs exist to deal with most of those components. But the batteries pose a different, and heretofore perplexing problem. Enter American Manganese Inc. (AMI), who say they have the answer to the world’s emerging EV market disposal problems….” READ THE ENTIRE ARTICLE     … Continue reading

Kootenay Silver’s, Jim McDonald interviewed by Katusa Research at the Cambridge Investment Conference

March 1, 2017 Editors Note from Dudley Pierce Baker We have know Jim McDonald for several years and are investors in KTN and KTN.WT. This interview with Katusa Research gives a great insight as to their possible growth and expansion of silver resources. For other exciting opportunities visit my website, http://CommonStockWarrants.com   Kootenay Silver Inc.   … Continue reading

President Trump: Replace The Dollar With Gold As The Global Currency To Make America Great Again

Ralph Benko , CONTRIBUTOR President Donald Trump speaks at the Conservative Political Action Conference, Friday, Feb. 24, 2017, in Oxon Hill, Md. (AP Photo/Alex Brandon) Inside President Trump’s otherwise “standard Trump stump speech” at CPAC was nestled what might be a most intriguing observation: Global cooperation, dealing with other countries, getting along with other countries is good, it’s very important. But there is no such thing as a global anthem, a global currency or a global flag. This is the United States of America that I’m representing. There’s a keen insight in there that could, just maybe, transform our lives, America, and the world. No “global currency?”  Was this, with the poetic observation that “there is no such thing as a global anthem…or a global flag,” just a trope? Or could it contain a political portent with potential high impact on world financial markets?  Let’s drill down. As it happens, there is a global currency. It’s called the “U.S. dollar.” Most international trade is priced in dollars. The Bretton Woods international monetary system invested the dollar, which then was defined as and (internationally) was legally convertible to gold at $35/oz, with global currency status.  France’s then-finance minister, later its president, Valéry  Giscard d’Estaing, called the “reserve currency” status of the dollar — its status, along with gold, as global currency — an “exorbitant privilege.” By this d’Estaing was alluding to the fact, as summarized at Wikipedia, that “As American economist Barry Eichengreen summarized: ‘It costs only a few cents for the … Continue reading

Doug Casey on the Single Wisest Thing You Can Do With Your Money

    Published February 25, 2017 Editor’s note: Over the next two days, we’re featuring timeless wisdom from Casey Research founder Doug Casey. Today, he shares the No. 1 thing you can do with your money to take control of your life and prosper in the years to come.     There’s a great deal more to becoming rich than buying the right investments and hoping for the best. The most important element in your strategy to win the battle for investment survival is your own psychology. You’ve heard that your attitude helps your health and your golf score; it’ll also improve your earning power. It’s not enough to liquidate your past financial mistakes. It’s more important to liquidate counterproductive attitudes, approaches, and methods of dealing with problems. The results that someone gets in life are an indication of how sound his approach toward life is. A sound philosophy of life gives good results. People with chaotic, unproductive, unhappy lives usually don’t have anyone to blame but themselves. They rarely have a strategy for living and thus have no foundation on which to build a strategy for investing. There’s plenty of good advice available on the subject. Marcus Aurelius’ Meditations, Ben Franklin’s autobiography, Norman Vincent Peale’s Power of Positive Thinking, Frank Bettger’s How I Raised Myself from Failure to Success in Selling, and Maxwell Maltz’s Psycho-Cybernetics are all helpful. One of the important things about the Greater Depression is that it will give you a chance to put your philosophy of life to the test. Almost … Continue reading

RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology

February 23, 2017 The Life Sciences Report RXi Pharmaceuticals’ proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It’s no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi’s President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. Management Q&A: View From the Top The Life Sciences Report: Thank you for joining us today. Would you tell us about RXi Pharmaceuticals Corp.’s (RXII:NASDAQ) RNAi therapeutic platform and sd-rxRNA compounds, what they are and how they are differentiated from your competitors? Pam Pavco: RXi has developed a proprietary self-delivering RNAi platform, termed sd-rxRNA, in which we’ve altered and improved upon the modifications and the structure of the standard RNAi compound. This novel class of compounds has improved drug-like properties that are potent, stable and specific with built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications. These improvements allow our compounds to be very efficiently taken up by cells. That is the one major differentiation between sd-rxRNA and RNAi compounds being used by other companies. The fact that sd-rxRNA is effectively taken up by cells means that sd-rxRNA is very amenable … Continue reading

Northern Dynasty – US Congressional Committee calls on EPA Administrator to withdraw Pebble Project veto

February 22, 2017   Editors Note from Dudley Pierce Baker http://CommonStockWarrants.com This company Press Release is out after the markets close today and after the shares and warrants have been punished badly of late. Perhaps this news will give some relief, we shall see …… February 22, 2017 Vancouver, BC – Northern Dynasty Minerals Ltd. (TSX: NDM; NYSE MKT: NAK) (“Northern Dynasty” or the “Company”) announces that the US House Committee on Science, Space and Technology has called on the new Administrator of the US Environmental Protection Agency (“EPA”) to rescind the federal agency’s 2014 regulatory action under Section 404(c) of the Clean Water Act to pre-emptively veto Alaska’s Pebble Project. A February 22, 2017 letter to EPA Administrator Scott Pruitt from Committee Chairman Lamar Smith states: “The Committee recommends that the incoming Administration rescind the EPA’s proposed determination to use Section 404(c) in a pre-emptive fashion for the Pebble Mine in Bristol Bay, Alaska. This simple action will allow a return to the long-established Clean Water Act permitting process and stop attempts by the EPA to improperly expand its authority. Moreover, it will create regulatory certainty for future development projects that will create jobs and contribute to the American economy.” Since 2014, Northern Dynasty and its 100%-owned subsidiary Pebble Limited Partnership (“Pebble Partnership”) have advanced a multi-prong strategy — including litigation, Congressional outreach, independent investigations, among other initiatives – to encourage EPA to withdraw its unprecedented regulatory action against Pebble. The Congressional Science, Space and Technology Committee has held … Continue reading

Donald Trump, Saudi Arabia, and the Petrodollar

Donald Trump, Saudi Arabia, and the Petrodollar By Nick Giambruno February 22, 2017 Obama pulled out his veto pen 12 times during his presidency. Congress only overrode him once… In late 2016, Obama vetoed the Justice Against Sponsors of Terrorism Act (JASTA). The bill would allow 9/11 victims to sue Saudi Arabia in US courts. With only months left in office, Obama wasn’t worried about the political price of opposing the bill. It was worth protecting Saudi Arabia and the petrodollar system, which underpins the US dollar’s role as the world’s premier currency. Congress didn’t see it that way though. Those up for reelection couldn’t afford to side with Saudi Arabia over US victims. So Congress voted to override Obama’s veto, and JASTA became the law of the land. The Saudis, quite correctly, see this as a huge threat. If they can be sued in US courts, their vast holdings of US assets are at risk of being frozen or seized. The Saudi foreign minister promptly threatened to sell all of the country’s US assets. Basically, Saudi Arabia was threatening to rip up the petrodollar arrangement, which underpins the US dollar’s role as the world’s premier currency. Donald Trump and the Saudis Unlike every president since the petrodollar’s birth, Donald Trump is openly hostile to Saudi Arabia. Recently he put this out on Twitter: Dopey Prince @Alwaleed_Talal wants to control our U.S. politicians with daddy’s money. Can’t do it when I get elected. The dopey prince that Trump is referring … Continue reading

Investing in Life Sciences Under the Trump Presidency

Source: Kristin McFarland for The Life Sciences Report  (2/16/17) Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. As of February, a great deal of uncertainty still remains as firms—and the stock market—try to predict the Trump administration’s next moves. There is a lot on the table right now that could work for—or against—life sciences companies, specifically pharmaceuticals. What does the future hold for pharmaceuticals under President Trump? This is the billion dollar question that no one really knows the answer to. The president hasn’t announced anything yet but based on what we do know, changes could be good for the pharmaceutical industry, bad, or leave things mostly unchanged. Here’s a quick summary: – President Trump was not as outspoken about his plans to reduce prescription prices as Mrs. Clinton was but he has remarked that something needs to be done about the prices of medications – The president would like to see a streamlined FDA approval process and favors an overall reduction in regulations – Mr. Trump also ran on the desire to lower the tax rate, specifically on businesses – Mr. Trump has mentioned the possibility of allowing Americans to import lower cost drugs from outside the U.S. – President Trump’s recent travel ban could impact the ability and desire for scientists in the international community to come … Continue reading

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source: The Life Sciences Report  (1/3/17) Editors Note: Dudley Baker here with http://CommonStockWarrants.com Several of the companies mentioned below have stock warrants trading which are in our databases with complete details. If you like the company, you must love the stock warrants trading on those companies. ________________________________________________________________________________ Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. The collection of small-cap biotechs on the 2017 Watchlist are developing therapies to address diverse indications including rare diseases, asthma, inflammatory bowel disease, spinal cord injury, hemophilia, and a number of cancers. The platforms are equally diverse, representing traditional biologics, cell therapies and vaccines. The panelists who selected the 2017 Small-Cap Biotech Watchlist are George Zavoico of JonesTrading Institutional Services, Raghuram (Ram) Selvaraju of Rodman and Renshaw, and Michael King of JMP Securities. The analysts will discuss their choices in depth at the Biotech Showcase 2017, running Jan. 9-11 at the Hilton San Francisco on Union Square downtown. The Watchlist panel discussion will take place at 8 a.m. on Wednesday, Jan. 11. The Approval Process in Action Infographic Michael King of JMP Securities selected these companies: Pieris Pharmaceuticals Inc. (PIRS:NASDAQ); ~$65M market cap. Pieris Pharmaceuticals has a proprietary biologics platform in the field of anticalins. Multiple therapeutic target areas for the therapy include anemia, asthma and immuno-oncology. WAVE Life Sciences Ltd. (WVE:NASDAQ); ~$723M market cap. This company … Continue reading